EcoDrugPlus

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSPMRG00000006895
Gene Symbol: CXCR4
3 Cross references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSPMRG00000010360
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Methyltransferase 1

Ensembl ID : ENSPMRG00000023733
Gene Symbol: DNMT1
3 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase I

Ensembl ID : ENSPMRG00000021425
Gene Symbol: TOP1
3 Cross references
271 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSPMRG00000016771
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase Ii Beta

Ensembl ID : ENSPMRG00000021101
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Emap Like 4

Ensembl ID : ENSPMRG00000004814
Gene Symbol: EML4
3 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Eph Receptor A2

Ensembl ID : ENSPMRG00000011820
Gene Symbol: EPHA2
1 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Eph Receptor A3

Ensembl ID : ENSPMRG00000009145
Gene Symbol: EPHA3
1 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Eph Receptor B4

Ensembl ID : ENSPMRG00000012153
Gene Symbol: EPHB4
3 Cross references
168 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPMRG00000021328
Gene Symbol: F2RL3
1 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSPMRG00000015437
Gene Symbol: FAU
3 Cross references
297 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).